-
-
-
-
-
-
-
Jefferies: 'we think BIIB stock could climb higher on the resiliency of the commercial franchise'
-
-
-
-
-
-
-
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
-
-
-
-
-
-
-
BMO Capital on Biogen (BIIB): Apellis deal 'sets a clear path for further expansion in nephrology'
-
-
-
-
-
-
-
Biogen completes acquisition of Alcyone Therapeutics
-
-
-
-
-
-
-
These 30 global stocks offer tactical and structural upside, says RBC
-
-
-
-
-
-
-
BTIG Reiterates Neutral Rating on Biogen (BIIB)
-
-
-
-
-
-
-
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and N
-
1,161,017 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

